drugset / Trial / NCT03051945

Endogenous Opioid Modulation by Ketamine

NCT03051945

Phase 3 Withdrawn University of Utah
RandomizedParallel-groupDouble-blindBasic science

Summary

Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.

Timeline

Start
2019-08
Primary completion
2019-08-01
Completion
2019-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous